<DOC>
	<DOCNO>NCT00727948</DOCNO>
	<brief_summary>Changes major angiogenic protein see follow initiation tamoxifen aromatase inhibitor therapy woman breast cancer . One source proteins circulate platelet pool . The investigator hypothesize addition anti-platelet property , agent aspirin use targeted anti-angiogenesis therapy . The investigator determine influence aspirin release angiogenic protein platelet 35 patient breast cancer .</brief_summary>
	<brief_title>The Effect Aspirin Angiogenesis Proteins Women Tamoxifen Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Histologically cytologically proven breast cancer Pre postmenopausal Age &gt; 18 Completed adjuvant nonhormonal therapy &gt; 30 day prior initiation study ( surgery and/or chemotherapy and/or radiation therapy ) Platelet count hemoglobin within normal range local lab within 30 day initiation study therapy Receiving tamoxifen therapy least 90 day prior initiation study therapy , expect continue therapy duration study ( 75 day ) Chemotherapy , radiation therapy surgery within 30 day study therapy Current use aspirin , antiplatelet anticoagulation agent continuous basis Prior history gastrointestinal central nervous system bleeding , document selfreported blood stool bright red blood per rectum</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Tamoxifen</keyword>
</DOC>